The administrative core with key clinical investigators from each participating clinical site will compile and submit FDA and harmonized IRB applications for approval. Dr. Sevick will be responsible for making the technologies available and overseeing overall execution of the primary project;Dr. Marshall will oversee regulatory and compliance aspects, and Dr. Berger along with participating clinicians will ensure patient safety and proper clinical trial design. Figure 2 illustrates the overall structure of the NTR team with the primary focus on clinical application of technologies to nodal staging of melanoma and breast cancer in Nuclear Medicine, the Operating Room, and Pathology. Task Specific Projects #1-4 and all Cores are housed within the Division of Molecular Imaging, of which Dr. Sevick is Division Head. Efforts demarked by a dashed box represent leveraged contributions provided without cost to the NTR. The administrative core comprised of Drs. Sevick, Marshall, and Berger will oversee all aspects of the NTR project, including technology deployment, compliance, and patient care and safety. Breast Center faculty (Chang, Gutierrez), Nuclear Medicine faculty (Wendt), Surgery faculty (Bonefas) who have clinical privileges at BTGH will assume patient care responsibilities in their specialty areas. Faculty with clinical privileges at the MEDVAMC in surgery (Berger, Albo), nuclear medicine (Bhargava) and pathology (Ittmann) will also assume patient care responsibilities in their specialty area. The Dan L. Duncan Cancer Center Clinical Trials Support Unit will assist in compliance activities and conduct audits to ensure adequate safety safeguards are in place during clinical studies. Quality assurance for GLP-compliant studies will fall under the Administrative Core, as will Quality Control for manufacturing procedures.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA136404-05
Application #
8381296
Study Section
Special Emphasis Panel (ZCA1-SRRB-9)
Project Start
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
5
Fiscal Year
2012
Total Cost
$88,742
Indirect Cost
$28,728
Name
University of Texas Health Science Center Houston
Department
Type
DUNS #
800771594
City
Houston
State
TX
Country
United States
Zip Code
77225
Rasmussen, John C; Aldrich, Melissa B; Tan, I-Chih et al. (2016) Lymphatic transport in patients with chronic venous insufficiency and venous leg ulcers following sequential pneumatic compression. J Vasc Surg Venous Lymphat Disord 4:9-17
Gonzalez-Garay, M L; Aldrich, M B; Rasmussen, J C et al. (2016) A novel mutation in CELSR1 is associated with hereditary lymphedema. Vasc Cell 8:1
Zhu, Banghe; Rasmussen, John C; Litorja, Maritoni et al. (2016) Determining the Performance of Fluorescence Molecular Imaging Devices Using Traceable Working Standards With SI Units of Radiance. IEEE Trans Med Imaging 35:802-11
Wang, Xuejuan; Aldrich, Melissa B; Yang, Zhi et al. (2016) Influence of chelator and near-infrared dye labeling on biocharacteristics of dual-labeled trastuzumab-based imaging agents. Chin J Cancer Res 28:362-9
Zhu, B; Sevick-Muraca, E M (2015) A review of performance of near-infrared fluorescence imaging devices used in clinical studies. Br J Radiol 88:20140547
Gao, Peng; Pinkston, Kenneth L; Wilganowski, Nathaniel et al. (2015) Deglycosylation of mAb by EndoS for improved molecular imaging. Mol Imaging Biol 17:195-203
Rasmussen, John C; Fife, Caroline E; Sevick-Muraca, Eva M (2015) Near-Infrared Fluorescence Lymphatic Imaging in Lymphangiomatosis. Lymphat Res Biol 13:195-201
Ghosh, Sukhen C; Pinkston, Kenneth L; Robinson, Holly et al. (2015) Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates. Nucl Med Biol 42:177-83
Agollah, Germaine D; Gonzalez-Garay, Manuel L; Rasmussen, John C et al. (2014) Evidence for SH2 domain-containing 5'-inositol phosphatase-2 (SHIP2) contributing to a lymphatic dysfunction. PLoS One 9:e112548
Rasmussen, John C; Herbst, Karen L; Aldrich, Melissa B et al. (2014) An abnormal lymphatic phenotype is associated with subcutaneous adipose tissue deposits in Dercum's disease. Obesity (Silver Spring) 22:2186-92

Showing the most recent 10 out of 33 publications